Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. (2018)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41467-017-02205-9
PubMed Identifier: 29321470
Publication URI: http://europepmc.org/abstract/MED/29321470
Type: Journal Article/Review
Volume: 9
Parent Publication: Nature communications
Issue: 1
ISSN: 2041-1723